~~<i id='21EBC148BF'><strike id='21EBC148BF'><tt id='21EBC148BF'><pre id='21EBC148BF'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

hotspot

author：hotspot 2025-09-14 21:45:43 - browse：3873

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Timeline: Key moments in fight for gay rights

leisure time

focus

hotspot

leisure time

hotspot

Wikipedia

1:58WindblowspalmtreesattheMedanobeachbeforethearrivalofhurricaneHilaryatLosCabosresortinBajaCalifor

WSS

A public health expert passes on football's full body collisions for youths

Cancer drug shortages' outsize impact on ovarian cancer patients

Novo pauses ads for weight loss drug Wegovy amid demand

How to fix the rural physician shortage in the U.S.

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Evacuations in place as 3 wildfires burn in eastern Washington state

leisure time

hotspot

leisure time

Drug repurposing or repositioning? The language matters

ActiGraph execs on goal of drug approvals with digital endpoints

The high cost of giving birth even with insurance

FDA approves first treatment for ultra

Anesthesiologist group: stop taking Ozempic before surgery

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

State Dept. review finds Biden bears some blame for Afghanistan failures

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

ChatGPT in medicine: STAT answers readers' burning questions

Biogen nominates mother of director’s child to replace him on board

focus

Biogen nominates mother of director’s child to replace him on board

New details revealed about Purdue's marketing of OxyContin

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

Senate panel passes drug pricing bills, but drops one PBM reform

ActiGraph execs on goal of drug approvals with digital endpoints

hotspot

leisure time

hotspot

Wikipedia